B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:193 |
|---|---|
| Enthalten in: |
British journal of haematology - 193(2021), 4 vom: 04. Mai, Seite 851-855 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bernabei, Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2021 Date Revised 28.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.17397 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322702534 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322702534 | ||
| 003 | DE-627 | ||
| 005 | 20231225182611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.17397 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1075.xml |
| 035 | |a (DE-627)NLM322702534 | ||
| 035 | |a (NLM)33713436 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bernabei, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2021 | ||
| 500 | |a Date Revised 28.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a cellular therapies | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a myeloma therapy | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a B-Cell Maturation Antigen |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a TNFRSF17 protein, human |2 NLM | |
| 650 | 7 | |a elotuzumab |2 NLM | |
| 650 | 7 | |a 1351PE5UGS |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a pomalidomide |2 NLM | |
| 650 | 7 | |a D2UX06XLB5 |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Tian, Lifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Garfall, Alfred L |e verfasserin |4 aut | |
| 700 | 1 | |a Melenhorst, J Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Lacey, Simon F |e verfasserin |4 aut | |
| 700 | 1 | |a Stadtmauer, Edward A |e verfasserin |4 aut | |
| 700 | 1 | |a Vogl, Dan T |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Vanessa E |e verfasserin |4 aut | |
| 700 | 1 | |a Plesa, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Regina M |e verfasserin |4 aut | |
| 700 | 1 | |a Waxman, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Levine, Bruce L |e verfasserin |4 aut | |
| 700 | 1 | |a June, Carl H |e verfasserin |4 aut | |
| 700 | 1 | |a Milone, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Adam D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 193(2021), 4 vom: 04. Mai, Seite 851-855 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:193 |g year:2021 |g number:4 |g day:04 |g month:05 |g pages:851-855 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.17397 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 193 |j 2021 |e 4 |b 04 |c 05 |h 851-855 | ||